本文選題：冠心病 + 冠狀動脈介入治療�。� 參考：《中國人民解放軍醫(yī)學(xué)院》2015年博士論文

【摘要】：研究背景及目的研究背景盡管隨著醫(yī)學(xué)的飛速發(fā)展以及診療技術(shù)的進(jìn)步,心血管疾病和大部分腫瘤的死亡率明顯下降,但是2013年最新人群死亡原因數(shù)據(jù)分析仍然顯示缺血性心臟病和腫瘤為全球死亡原因前兩位。冠心病和腫瘤已經(jīng)成為嚴(yán)重威脅我國人群健康的多發(fā)病和常見病,特別是兩者還具有相同的發(fā)病人群(老年人)和重疊的危險因素(如吸煙、不均衡飲食、缺少鍛煉等),因此常常合并存在。隨著我國人口老齡化的進(jìn)程,在臨床上冠心病合并腫瘤的患者也越來越多,針對這部分患者的診斷和治療尤其是手術(shù)策略,越來越成為心血管醫(yī)生和腫瘤�？漆t(yī)生不能忽視和不可回避的重要臨床問題。在合并冠心病的腫瘤患者中,如果需要外科手術(shù)切除腫瘤病灶,一定會首先評估心臟情況,如果發(fā)現(xiàn)心臟處于嚴(yán)重的不穩(wěn)定的缺血狀態(tài),會大大增加外科手術(shù)圍術(shù)期的急性心臟事件發(fā)生的風(fēng)險,或者不能耐受外科手術(shù)。對于這些患者,必須首先對心臟行再血管化治療,才有機(jī)會行外科手術(shù)切除腫瘤病灶,并且心臟本身也需要盡快再血管化治療,降低嚴(yán)重冠狀動脈狹窄給心臟本身帶來的風(fēng)險。因此術(shù)前準(zhǔn)確評估患者心臟缺血程度和風(fēng)險,做好再血管化治療,并在最短時間內(nèi)進(jìn)行腫瘤的外科限期手術(shù),將會對這類患者產(chǎn)生巨大獲益,具有重要的臨床意義。由于治療上存在有一定的矛盾,如何對冠心病合并腫瘤患者做好預(yù)防性的再血管化治療,一直是困擾著心臟科和外科醫(yī)生的難題,其中最核心的問題就是：如何平衡好患者的缺血出血風(fēng)險和手術(shù)獲益。AHA/ACC已經(jīng)有明確指南,建議在非心臟手術(shù)前,對一些嚴(yán)重的心肌缺血患者應(yīng)該進(jìn)行預(yù)防性的再血管化治療；而腫瘤病灶切除則屬于外科限期手術(shù),在各方面情況允許時應(yīng)盡快手術(shù)。所以,目前爭論的焦點(diǎn)主要集中在：一、冠狀動脈介入手術(shù)后最快多長時間可以進(jìn)行腫瘤手術(shù)?二、圍術(shù)期抗血小板、抗栓藥物如何應(yīng)用?本研究回顧了解放軍總醫(yī)院近6年的冠心病合并腫瘤患者,分析了先冠狀動脈介入治療(PCI)后再行外科手術(shù)患者的臨床資料、圍術(shù)期用藥及預(yù)后,對患者死亡原因的風(fēng)險進(jìn)行析因分析,探討了PCI術(shù)后腫瘤切除最佳時機(jī)和圍術(shù)期合理應(yīng)用抗血小板、抗栓藥物的問題。總結(jié)治療經(jīng)驗以及對預(yù)后的影響,旨在為提高腫瘤合并冠心病患者的治療療效、延長患者壽命提供臨床依據(jù)和指導(dǎo)。目的闡明冠狀動脈介入治療對腫瘤合并冠心病患者限期外科手術(shù)的安全性的影響,明確不同類型支架對腫瘤患者預(yù)后的影響是否不同。方法2006年03月-2012年03月在我科住院的冠心病合并腫瘤患者共209例,根據(jù)AHA/ACC對冠心病行非心臟手術(shù)前是否需要再血管化的指南,其中122例行先行冠狀動脈支架植入術(shù),4周后再行腫瘤病灶切除術(shù),為支架+腫瘤切除組；另外87例行單純冠狀動脈造影后次日轉(zhuǎn)外科行腫瘤病灶切除術(shù),為造影+腫瘤切除組。比較分析兩組患者的基本資料、外科圍術(shù)期安全性。隨訪支架+腫瘤切除組患者的生存情況、科圍術(shù)期心血管事件發(fā)生情況。采用單因素、多因素生存分析的方法分析影響PCI術(shù)后短期內(nèi)行腫瘤切除手術(shù)患者預(yù)后的影響因素。結(jié)果1、122位冠心病合并腫瘤患者行冠脈介入治療,共植入220枚支架,其中196(89.1%)枚為藥物洗脫支架,24(10.9%)枚金屬裸支架。手術(shù)即刻成功率為100%,支架后擴(kuò)張率為100%。2、1例消化道腫瘤患者在冠狀動脈支架術(shù)后3天出現(xiàn)消化道出血,立即給與輸血,調(diào)整抗血小板、抗凝藥物的使用,急診行外科手術(shù)。75(61.5%)例患者在冠狀動脈支架術(shù)后第4至6周在我院完成了腫瘤病灶切除術(shù),26(21.3%)例患者在第6至10周內(nèi)完成了腫瘤病灶切除術(shù),20(16.4%)例患者在第10周之后完成了腫瘤病灶切除術(shù)。3、冠狀動脈介入治療術(shù)后,在外科圍術(shù)期應(yīng)用低分子肝素替代抗血小板藥物治療,患者術(shù)中出血量、術(shù)后引流量、手術(shù)時間、術(shù)后住院時間和應(yīng)用抗血小板、抗凝藥物的患者比較,無統(tǒng)計學(xué)差異；支架+腫瘤切除組患者在圍術(shù)期沒有支架內(nèi)血栓發(fā)生。4、支架+腫瘤切除組患者中位隨訪時間31個月,2年生存率為82.79%,3年生存率為68.85%。單因素及多因素分析發(fā)現(xiàn)PCI至手術(shù)間隔時間、CEA水平和心率對PCI術(shù)后行腫瘤切除患者生存時間有影響,而植入支架類型、植入支架冠狀動脈支數(shù)等因素對其生存時間無影響。結(jié)論1、對PCI術(shù)后短期內(nèi)行外科腫瘤切除術(shù)的患者,圍術(shù)期應(yīng)用低分子肝素替代抗血小板藥物治療是安全的；2、PCI術(shù)后6周內(nèi)行腫瘤切除、心率控制在90次/分以下,是影響該組患者預(yù)后的保護(hù)因素；3、植入藥物洗脫支架和金屬裸支架組患者相比,圍術(shù)期安全性及遠(yuǎn)期預(yù)后均無統(tǒng)計學(xué)差異。
[Abstract]:Background and objective research background, although with the rapid development of medicine and the progress of diagnosis and treatment technology, the mortality of cardiovascular disease and most tumors has declined significantly, but the analysis of the cause of death of the latest population in 2013 still shows that two of the leading causes of global death are ischemic heart disease and tumor. In order to seriously threaten the prevalence and common diseases of the health of the population in our country, especially in the same population (old people) and the risk factors of overlapping (such as smoking, unbalanced diet, lack of exercise, etc.), it is often combined. With the aging process of our population, patients with coronary heart disease combined with tumors are becoming more and more in the clinic. More and more, the diagnosis and treatment of this part of the patients, especially the surgical strategy, are becoming more and more important and important clinical problems that can not be ignored and unavoidable. In the patients with coronary heart disease, if surgical resection of the tumor is needed, the heart condition will be evaluated first, if the heart is found. Severe and unstable ischemic state can greatly increase the risk of acute cardiac events during surgical perioperative period, or can not tolerate surgery. For these patients, it is necessary to revascularization of the heart first to have the opportunity to surgical resection of the tumor, and the heart itself needs to be revascularized as soon as possible. Treatment, reducing the risk of serious coronary artery stenosis to the heart itself. Therefore, accurate assessment of the degree and risk of heart ischemia, revascularization, and surgical limited surgery within the shortest time will be of great benefit to these patients and have important clinical significance. A certain contradiction, how to do preventive revascularization for patients with coronary heart disease and cancer has been a difficult problem for the cardiology department and surgeons. The most important problem is: how to balance the risk of ischemia and bleeding in patients and the benefit of operation.AHA/ACC has a clear guide, it is suggested that before the non cardiac surgery, some Patients with severe myocardial ischemia should be treated with prophylactic revascularization; tumor resection is a surgical limit operation and should be operated as soon as possible in all aspects. Therefore, the focus of the current debate is: (1) how soon after coronary intervention is the fastest time for tumor surgery? Two, perioperative period How to use antiplatelet and antithrombotic drugs? This study reviewed the recent 6 years of coronary heart disease combined with tumor patients in the General Hospital of PLA, analyzed the clinical data of patients undergoing coronary intervention (PCI), the perioperative medication and prognosis, analysis of the risk of death of the patients, and discussed the tumor resection after PCI. In order to improve the therapeutic efficacy of the patients with coronary heart disease and prolong the life span of the patients with coronary heart disease, the aim of this study is to provide the clinical basis and guidance to improve the therapeutic effect and prolong the life span of the patients with coronary heart disease. The effect of the safety of the operation is to determine whether different types of stents have different effects on the prognosis of cancer patients. Methods 209 cases of coronary heart disease combined with tumors were hospitalized in our department in 2006, -2012, 03 months, according to the guidelines for revascularization for coronary heart disease before non cardiac surgery, and 122 of them were first coronary artery branch. 4 weeks later, the tumor resection was performed for the stent plus tumor resection group, and the other 87 cases were treated with the tumor resection group after the simple coronary angiography. The basic data of the two groups were compared and analyzed. The safety of surgical perioperative period was compared and the survival of the patients in the stent and tumor resection group was followed up. A single factor and multifactor survival analysis were used to analyze the factors affecting the prognosis of patients undergoing PCI resection in the short term. Results 1122 patients with CAD and tumor were treated with coronary intervention, and 220 stents were implanted, of which 196 (89.1%) were drug-eluting stents and 24 (10.9%). A bare metal stent. The immediate success rate of the operation was 100%. The poststent dilatation rate was 3 days after the coronary stent implantation in 100%.2,1 patients with digestive tract tumors. The blood transfusion was given immediately, the antiplatelet and anticoagulants were adjusted, and the emergency operation was performed in.75 (61.5%) patients fourth to 6 weeks after coronary artery stenting. Tumor excision was performed in the hospital. 26 (21.3%) patients completed tumor resection in sixth to 10 weeks. 20 (16.4%) patients completed tumor resection.3 after tenth weeks. After coronary intervention, low molecular weight heparin was used to replace antiplatelet drugs in surgical perioperative period. The amount of intraoperative bleeding and postoperative bleeding were observed. There was no statistical difference in the flow rate, the time of operation, the time of postoperative hospitalization and the use of antiplatelet and anticoagulant drugs. There was no stent thrombosis in the perioperative period of the stent plus tumor resection group.4, the median follow-up time of the stent + tumor resection group was 31 months, the 2 year survival rate was 82.79%, and the 3 year survival rate was 68.85%. single factor and more. Factor analysis found that PCI to operation interval time, CEA level and heart rate have an influence on the survival time of the patients undergoing tumor resection after PCI, and the type of stent implantation and the number of coronary artery support implantation have no influence on the survival time. Conclusion 1, low molecular weight heparin (LMWH) was used in the perioperative period of postoperative intraoperative surgical swollen tumor resection for PCI. The replacement of antiplatelet drugs was safe; 2, the tumor resection was performed within 6 weeks after PCI and the heart rate control was below 90 times per cent. It was a protective factor affecting the prognosis of the patients in this group. 3, there was no statistical difference between the perioperative safety and the long term after implantation of drug eluting stents and bare metal stents.
【學(xué)位授予單位】：中國人民解放軍醫(yī)學(xué)院
【學(xué)位級別】：博士
【學(xué)位授予年份】：2015
【分類號】：R541.4;R730.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 孫惠華;;多功能手術(shù)解剖器在外科手術(shù)中的應(yīng)用[J];護(hù)理研究(下旬版);2006年21期

2 尹建榮;;外科手術(shù)前后飲食及心護(hù)理[J];中國傷殘醫(yī)學(xué);2010年02期

3 ;疾病帶來的啟示！[J];養(yǎng)生大世界(B版);2010年05期

4 孫宏濤;;走近無血外科手術(shù)[J];百科知識;2010年23期

5 王履渝;外科手術(shù)的新飛躍──德國“鑰匙孔”式手術(shù)[J];國外科技動態(tài);1994年04期

6 鄧承祺;外科手術(shù)與彌散性血管內(nèi)凝血[J];中國實用內(nèi)科雜志;2000年06期

7 黃鳳瑞;熟練掌握外科手術(shù)操作基本功[J];前衛(wèi)醫(yī)藥雜志;2000年03期

8 Gurney　Williams,饒新華;未來的外科手術(shù)室[J];世界科學(xué);2000年09期

9 吳肇漢;重視肝硬變對外科手術(shù)的影響[J];中國實用外科雜志;2001年10期

10 周潔 ,白木;人類進(jìn)入機(jī)器人外科手術(shù)時代[J];機(jī)電一體化;2001年05期

相關(guān)會議論文 前10條

1 陳嬌;;肥胖外科手術(shù)的術(shù)前后護(hù)理[A];全國外科護(hù)理學(xué)術(shù)交流暨專題講座會議、全國神經(jīng)內(nèi)、外科護(hù)理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2010年

2 廖愛芬;;老年病人外科手術(shù)后的護(hù)理[A];中國老年學(xué)學(xué)會2006年老年學(xué)學(xué)術(shù)高峰論壇論文集[C];2006年

3 嵇佳;江燕;;肥胖外科手術(shù)的術(shù)前后護(hù)理[A];中華護(hù)理學(xué)會《護(hù)士條列》解析培訓(xùn)會、中華護(hù)理學(xué)會2008年“中國護(hù)理事業(yè)發(fā)展”論壇暨全國護(hù)理新理論、新技術(shù)、新方法研討會論文匯編[C];2008年

4 李玉娟;陳翠芳;;外科手術(shù)部位感染預(yù)防與控制對策[A];中國醫(yī)院協(xié)會第十八屆全國醫(yī)院感染管理學(xué)術(shù)年會論文資料匯編[C];2011年

5 趙子牛;王勝利;胡型銻;趙琦峰;杜杰;章岳峰;吳蓉洲;;小兒繼發(fā)孔型房間隔缺損介入治療和外科手術(shù)的對比研究[A];2005年浙江省小兒外科學(xué)術(shù)會議論文匯編[C];2005年

6 趙子牛;王勝利;胡型銻;趙琦峰;杜杰;章岳峰;吳蓉洲;;小兒繼發(fā)孔型房間隔缺損介入治療和外科手術(shù)的對比研究[A];第八屆華東六省一市胸心血管外科學(xué)術(shù)會議論文匯編[C];2005年

7 馮曉燕;丁小華;馮麗;;難治性癲癇外科手術(shù)治療中的健康教育[A];2007浙江省神經(jīng)外科學(xué)學(xué)術(shù)年會論文匯編[C];2007年

8 李萍;;現(xiàn)代耳外科手術(shù)護(hù)士的技能和培訓(xùn)[A];全國五官科護(hù)理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2008年

9 張燕;李蓉;劉華英;李霞;;經(jīng)尿道前列腺電切術(shù)的術(shù)中配合與體會[A];第十五屆全國泌尿外科學(xué)術(shù)會議論文集[C];2008年

10 徐鵬飛;;小兒室間隔缺損介入治療與外科手術(shù)對比研究[A];第十三次全國心血管病學(xué)術(shù)會議論文集[C];2011年

相關(guān)重要報紙文章 前10條

1 秦健勇 廣州醫(yī)學(xué)院荔灣醫(yī)院腫瘤科副主任醫(yī)師;外科手術(shù)：治愈癌癥的基石[N];醫(yī)藥經(jīng)濟(jì)報;2014年

2 胡延濱 李雪;中醫(yī)獲得“外科手術(shù)藝術(shù)獎”背后[N];健康報;2012年

3 中國醫(yī)學(xué)科學(xué)院整形外科醫(yī)院教授 李森愷;重視外科手術(shù)的精細(xì)管理[N];健康報;2012年

4 張明堯;外科手術(shù)進(jìn)入全新微創(chuàng)時代[N];科技日報;2001年

5 夏軍平 寧習(xí)源;五成常規(guī)外科手術(shù)可用微創(chuàng)完成[N];廣東科技報;2004年

6 記者 曹斯　通訊員 銀春林;廣總醫(yī)院成功實施百歲老人外科手術(shù)[N];南方日報;2010年

7 河南中醫(yī)學(xué)院 孟長�！⊥踔斡�;誰動了我們的手術(shù)刀[N];中國中醫(yī)藥報;2011年

8 王高;減肥外科手術(shù)比預(yù)想的更危險[N];健康報;2005年

9 本報駐巴黎記者　 宋斌;法國完成首例“太空外科手術(shù)”[N];光明日報;2006年

10 通訊員 賈澤明　龔連生 記者 徐蘭山;中韓合作首例無疤痕外科手術(shù)成功[N];科技日報;2009年

相關(guān)博士學(xué)位論文 前1條

1 王錦達(dá);冠心病合并腫瘤患者介入治療后外科限期手術(shù)安全性的研究[D];中國人民解放軍醫(yī)學(xué)院;2015年

相關(guān)碩士學(xué)位論文 前7條

1 張冉;山西省耐多藥肺結(jié)核病外科手術(shù)依從性調(diào)查[D];山西醫(yī)科大學(xué);2010年

2 徐鵬飛;小兒室間隔缺損介入治療與外科手術(shù)對比研究[D];重慶醫(yī)科大學(xué);2011年

3 馮娟;經(jīng)導(dǎo)管封堵和外科手術(shù)治療動脈導(dǎo)管未閉對照試驗的Meta分析[D];山東大學(xué);2007年

4 杜朝峻;嬰幼兒法洛四聯(lián)癥的外科手術(shù)治療[D];安徽醫(yī)科大學(xué);2011年

5 李麗麗;ESD術(shù)與外科手術(shù)治療消化道早癌的對比研究[D];青島大學(xué);2013年

6 蔣正楠;45例良性對稱性脂肪瘤病臨床分析[D];廣西醫(yī)科大學(xué);2014年

7 蔣廳;甲狀腺癌外科手術(shù)進(jìn)展[D];重慶醫(yī)科大學(xué);2012年

，

本文編號：1938218